Bioperfectus

BioPerfectus is a leading molecular diagnostics company specializing in in-vitro diagnostic (IVD) reagents, instruments, and services for infectious diseases and women's and children's health. The company manufactures and distributes over 700 products including real-time PCR systems, automated nucleic acid extraction workstations, and comprehensive diagnostic solutions for measles, rubella, influenza, HPV/cervical cancer screening, vector-borne diseases (malaria, dengue, Zika, chikungunya), mpox, and sexually transmitted infections. BioPerfectus offers fully integrated PCR workflows combining its SAW series automated extraction systems with STC series real-time PCR instruments, requiring minimal daily hands-on time. With over 100 CE-marked assays and distribution across more than 100 countries, the company serves medical institutions, clinical diagnostic centers (CDCs), and clinical laboratories. Founded in 2010 and publicly listed on the Shanghai Stock Exchange, BioPerfectus emphasizes point-of-care testing innovation, nucleic acid extraction technology, and outbreak preparedness, with partnerships including the World Health Organization.